Patient-derived xenografts and organoids model therapy response in prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-derived xenografts and organoids model therapy response in prostate cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-20
DOI
10.1038/s41467-021-21300-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
- (2020) Laura S. Graham et al. PLoS One
- The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
- (2020) Nallasivam Palanisamy et al. CLINICAL CANCER RESEARCH
- Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
- (2020) Pedro Barata et al. Journal for ImmunoTherapy of Cancer
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis
- (2019) Michael A. Augello et al. CANCER CELL
- Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
- (2019) Jumpei Kondo et al. Cells
- Xenograft and organoid model systems in cancer research
- (2019) Margit Bleijs et al. EMBO JOURNAL
- Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
- (2019) In-Wha Kim et al. Frontiers in Oncology
- Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
- (2019) Minsuh Kim et al. Nature Communications
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- (2019) Lisanne F. van Dessel et al. Nature Communications
- Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
- (2019) Goutam Chakraborty et al. CLINICAL CANCER RESEARCH
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
- (2018) Michael L. Beshiri et al. CLINICAL CANCER RESEARCH
- CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma
- (2018) Sofia Karkampouna et al. JOURNAL OF PATHOLOGY
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- Patient derived organoids to model rare prostate cancer phenotypes
- (2018) Loredana Puca et al. Nature Communications
- Microsatellite instability in prostate cancer by PCR or next-generation sequencing
- (2018) Jennifer A. Hempelmann et al. Journal for ImmunoTherapy of Cancer
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Microsatellite instability in prostate cancer and response to immune checkpoint blockade.
- (2018) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.
- (2018) Pasquale Rescigno et al. JOURNAL OF CLINICAL ONCOLOGY
- Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models
- (2018) Nora M. Navone et al. PROSTATE
- Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
- (2018) Sandro Nuciforo et al. Cell Reports
- Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
- (2018) Yi Ma et al. BMC Medical Genetics
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
- (2017) Holly M. Nguyen et al. PROSTATE
- Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
- (2017) Renea A. Taylor et al. Nature Communications
- Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
- (2017) Chantal Pauli et al. Cancer Discovery
- Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways
- (2016) Gabriel A. Rabinovich et al. JOURNAL OF MOLECULAR BIOLOGY
- Organoid culture systems for prostate epithelial and cancer tissue
- (2016) Jarno Drost et al. Nature Protocols
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
- (2015) Gail P. Risbridger et al. EUROPEAN UROLOGY
- Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
- (2015) D. Sanford et al. HAEMATOLOGICA
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice
- (2015) Christian Wetterauer et al. PROSTATE
- SPOP mutation leads to genomic instability in prostate cancer
- (2015) Gunther Boysen et al. eLife
- Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
- (2015) D. Sanford et al. HAEMATOLOGICA
- Organoid Cultures Derived from Patients with Advanced Prostate Cancer
- (2014) Dong Gao et al. CELL
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
- (2014) Colin C. Pritchard et al. Nature Communications
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
- (2013) Beifang Niu et al. BIOINFORMATICS
- High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
- (2013) D. Lin et al. CANCER RESEARCH
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions
- (2012) Omer Raheem et al. Journal of Translational Medicine
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial‡
- (2011) A. J. Zurita et al. ANNALS OF ONCOLOGY
- The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers
- (2011) Danny Vesprini et al. CUAJ-Canadian Urological Association Journal
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
- (2011) Emma K. Beardsley et al. INVESTIGATIONAL NEW DRUGS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
- (2010) Srikala S. Sridhar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate Tumors
- (2010) Carmen Priolo et al. AMERICAN JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now